Skip to main content
HRTX logo

HRTX · Heron Therapeutics, Inc. · Documents

Track HRTX — free
$0.27 +0.01 (+2.23%) Play latest call Q2 2026 earnings call transcript
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19 3.61M Avg daily vol (3M) 4.54M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $154.9M up 7.4% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $35.25M down 7.8% 10-Q filed Nov 9, 2026 Latest results CorMedix Therapeutics to acquire substantially all Heron assets 8-K filed Nov 9, 2026 Earnings call Q2 2026 earnings call Held Aug 10, 2026
2026
Nov 9
Proxy statement DEFA14A
CorMedix agrees to buy substantially all Heron Therapeutics assets

CorMedix agreed to acquire substantially all Heron Therapeutics assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, in a cash and stock transaction. Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other customary conditions.

Read from the first part of this long document
3 source passages
This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Heron Therapeutics, Inc., a Delaware corporation (“Heron” or the “Company”) with a proxy statement related to a proposed transaction in which the Company will sell substantially all of its assets to CorMedix Inc., a Delaware corporation (“CorMedix”), other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (“NOLs”) and certain other tax attributes, and CorMedix has agreed to acquire those assets and assume certain liabilities of the Company, upon the terms and subject to the conditions set forth in the Asset Purchase Agreement, dated November 8, 2026, by and between the Company and CorMedix (the “Proposed Transaction”). Earlier today, we announced that CorMedix has agreed to acquire substantially all of Heron’s assets, including all four of Heron’s commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — in a cash and stock transaction. We expect the transaction to close in the first quarter of 2027, subject to approval by Heron stockholders, regulatory clearance, and other customary closing conditions. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Heron agrees $145.0 million asset sale to CorMedix

Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.

Revenue $35.25M ▼ 7.8% Net loss $5.01M Diluted EPS -$0.03
Read from the MD&A section
3 source passages
On November 8, 2026, the Company entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with CorMedix, pursuant to which it has agreed to sell substantially all of its assets to CorMedix, other than certain excluded assets, including its federal income tax net operating loss carryforwards (the "NOLs") and certain other tax attributes, and CorMedix has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Asset Purchase Agreement (the "Asset Sale"). As consideration for the Asset Sale, CorMedix has agreed to (i) issue to the Company 14,583,333 shares of CorMedix common stock, (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company's closing cash and net working capital as set forth in the Asset Purchase Agreement, of which $2.0 million will be deposited into escrow, at the closing of the Asset Sale to secure post-closing adjustments to the cash consideration, which post-closing adjustments may not exceed $10.0 million in either direction, (iii) pay to the Company royalties equal to 5.0% of the amount, if any, by which aggregate annual net sales of CINVANTI, SUSTOL and the products covered by the Company's multi-product Development and License Agreement (the "License Agreement") with Long Grove Pharmaceuticals, LLC, a Delaware limited liability company ("Long Grove"), exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable, on the terms set forth in the Asset Purchase Agreement, (iv) pay to the Company earn-out payments of $25.0 million if net sales of ZYNRELEF for calendar year 2028 equal or exceed $65.0 million and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable at CorMedix’s election in cash, shares of CorMedix common stock or a combination thereof (provided that any portion that would cause the aggregate shares of CorMedix common stock issued under the Asset Purchase Agreement to exceed 19.9% of the CorMedix common stock outstanding as of the closing of the Asset Sale will be paid in cash), if and when payable, on the terms set forth in the Asset Purchase Agreement and (v) assume certain of the Company's liabilities as specified in the Asset Purchase Agreement. The Asset Sale, which has been unanimously approved by the board of directors of the Company (the "Board"), is currently expected to close in the first quarter of 2027, subject to approval by the Company's stockholders and the satisfaction of other customary closing conditions. Open the document at this passage
Nov 9
Proxy statement DEFA14A
CorMedix Agrees to Buy Substantially All Assets

Heron Therapeutics, Inc. agreed on November 8, 2026 to sell substantially all assets to CorMedix Inc. for $145.0 million cash and 14,583,333 CorMedix shares, plus royalties and contingent earn-out payments, subject to stockholder and regulatory approvals.

Read from the first part of this long document
2 source passages
On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (the “NOLs”) and certain other tax attributes, and the Buyer has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”). As consideration for the Asset Sale, the Buyer has agreed to (i) issue 14,583,333 shares of common stock, par value $0.001 per share, of the Buyer (“Buyer common stock”) (the “Stock Consideration”), (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company’s closing cash and net working capital as set forth in the Purchase Agreement (the “Cash Consideration”), of which $2.0 million will be deposited into escrow with Citibank, N.A., as escrow agent, at the Closing (as defined below) to secure post-Closing adjustments to the Cash Consideration, which post-Closing adjustments may not exceed $10.0 million in either direction, (iii) pay to the Company royalties equal to 5.0% of the amount, if any, by which aggregate annual net sales of CINVANTI®, SUSTOL® and the products covered by the Company’s multi-product Development and License Agreement exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable, on the terms set forth in the Purchase Agreement, (iv) pay to the Company earn-out payments of $25.0 million if net sales of ZYNRELEF® for calendar year 2028 equal or exceed $65.0 million and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable at the Buyer’s election in cash, shares of Buyer common stock or a combination thereof (provided that any portion that would cause the aggregate shares of Buyer common stock issued under the Purchase Agreement to exceed 19.9% of the Buyer common stock outstanding as of the closing of the Asset Sale (the “Closing”) will be paid in cash), if and when payable, on the terms set forth in the Purchase Agreement and (v) assume certain liabilities of the Company as specified in the Purchase Agreement. Open the document at this passage
Nov 9
Current report 8-K
CorMedix Therapeutics to acquire substantially all Heron assets

Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.

Financial results
3 source passages
Heron Therapeutics Announces Third Quarter 2026 Financial Results Heron and CorMedix Therapeutics (“CorMedix”) announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all the assets of Heron (the “Asset Sale”). The Asset Sale is subject to approval by Heron’s stockholders and other customary closing conditions. Heron generated total net revenue of $35.3 million in Q3 2026, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. Open the document at this passage
Nov 9
Current report 8-K Events of Nov 8
Heron Therapeutics agrees to sell assets to CorMedix

On November 8, 2026, Heron Therapeutics agreed to sell substantially all assets to CorMedix for $145.0 million cash, subject to closing-cash and net-working-capital adjustments, plus 14,583,333 CorMedix shares, subject to stockholder approval.

Entered into a material agreement, Change to shareholders' rights, Regulation FD disclosure Read from the first part of this long document
3 source passages
On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (the “NOLs”) and certain other tax attributes, and the Buyer has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”). As consideration for the Asset Sale, the Buyer has agreed to (i) issue 14,583,333 shares of common stock, par value $0.001 per share, of the Buyer (“Buyer common stock”) (the “Stock Consideration”), (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company’s closing cash and net working capital as set forth in the Purchase Agreement (the “Cash Consideration”) The Purchase Agreement, the Asset Sale and other transactions contemplated by the Purchase Agreement must also be approved by the holders of a majority of the issued and outstanding shares of the Company’s common stock (“Common Stock”) entitled to vote thereon (the “Company Stockholder Approval”). Open the document at this passage
Sep 29
Current report 8-K Events of Sep 23
Entered into a material agreement

On September 23, 2026, Heron Therapeutics entered a Development and License Agreement with Long Grove, securing exclusive U.S. sales rights for certain products, nonexclusive manufacturing rights, and obligations to pay milestones, royalties and expense reimbursements.

Aug 10
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $37.67M ▲ 1.3% Net loss $5.49M Diluted EPS -$0.03
Jun 2
Current report 8-K
Other events AI summary on its way
May 11
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $34.71M ▼ 10.8% Net loss $8.11M Diluted EPS -$0.04
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $154.9M ▲ 7.4% Net loss $20.2M Diluted EPS -$0.12
2025
Showing 1–50 of 175 documents
Key facts CIK 818033 CUSIP 427746102 13F (30d) 157 filings 141 filers Visit website Investor relations